US Stock MarketDetailed Quotes
HROW Harrow
- 49.910
- -2.110-4.06%
Close Nov 12 16:00 ET
- 49.910
- 0.0000.00%
Post 20:02 ET
1.77BMarket Cap-52536P/E (TTM)
53.880High48.670Low725.35KVolume52.500Open52.020Pre Close36.48MTurnover2.75%Turnover RatioLossP/E (Static)35.48MShares59.23052wk High30.25P/B1.32BFloat Cap8.72052wk Low--Dividend TTM26.41MShs Float59.230Historical High--Div YieldTTM10.02%Amplitude0.025Historical Low50.290Avg Price1Lot Size
About Harrow Company
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Company Profile
SymbolHROW
Company NameHarrow
Listing DateFeb 8, 2013
Founded2006
CEOMr. Mark L. Baum
MarketNASDAQ
Employees315
Fiscal Year Ends12-31
Address102 Woodmont Boulevard,Suite 610
CityNashville
ProvinceTennessee
CountryUnited States of America
Zip Code37205
Phone1-615-733-4730
Websitehttp://www.harrow.com
Company Executives
- Name
- Position
- Salary
- John Saharek
- Chief Commercial Officer; President and Chief Executive Officer, ImprimisRx
- 5.82M
- Mark L. Baum
- Chief Executive Officer and Chairman of the Board
- 15.26M
- Andrew R. Boll
- Chief Accounting Officer, Chief Financial Officer and Corporate Secretary
- 7.13M
- Lauren P. Silvernail
- Director
- --
- Dr. Adrienne L. Graves,PhD
- Director
- --
- Dr. Martin A. Makary, M.D.
- Independent Director
- 205.00K
- Teresa F. Sparks
- Independent Director
- 227.50K
- Perry J. Sternberg
- Lead Independent Director
- 202.50K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
